ZA200404718B - Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor - Google Patents
Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor Download PDFInfo
- Publication number
- ZA200404718B ZA200404718B ZA200404718A ZA200404718A ZA200404718B ZA 200404718 B ZA200404718 B ZA 200404718B ZA 200404718 A ZA200404718 A ZA 200404718A ZA 200404718 A ZA200404718 A ZA 200404718A ZA 200404718 B ZA200404718 B ZA 200404718B
- Authority
- ZA
- South Africa
- Prior art keywords
- dosage form
- controlled release
- formula
- release dosage
- cetpi
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title claims description 77
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 title claims description 69
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 title claims description 53
- 238000013270 controlled release Methods 0.000 title claims description 53
- 239000003814 drug Substances 0.000 claims description 31
- 229940079593 drug Drugs 0.000 claims description 31
- KEWSCDNULKOKTG-UHFFFAOYSA-N 4-cyano-4-ethylsulfanylcarbothioylsulfanylpentanoic acid Chemical compound CCSC(=S)SC(C)(C#N)CCC(O)=O KEWSCDNULKOKTG-UHFFFAOYSA-N 0.000 claims description 23
- 102100037637 Cholesteryl ester transfer protein Human genes 0.000 claims description 23
- 101000880514 Homo sapiens Cholesteryl ester transfer protein Proteins 0.000 claims description 23
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 12
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000006185 dispersion Substances 0.000 claims description 8
- 230000005764 inhibitory process Effects 0.000 claims description 8
- 238000008214 LDL Cholesterol Methods 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 6
- 238000001556 precipitation Methods 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 claims description 2
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 230000036470 plasma concentration Effects 0.000 claims description 2
- CMSGWTNRGKRWGS-NQIIRXRSSA-N torcetrapib Chemical compound COC(=O)N([C@H]1C[C@@H](CC)N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OCC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CMSGWTNRGKRWGS-NQIIRXRSSA-N 0.000 claims description 2
- 229950004514 torcetrapib Drugs 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 9
- 102000015779 HDL Lipoproteins Human genes 0.000 description 9
- 208000029078 coronary artery disease Diseases 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 230000003204 osmotic effect Effects 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 208000032928 Dyslipidaemia Diseases 0.000 description 3
- 108010028554 LDL Cholesterol Proteins 0.000 description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 241000282412 Homo Species 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- -1 cholesteryl ester Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000013563 matrix tablet Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000001434 dietary modification Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000000207 pro-atherogenic effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35371902P | 2002-02-01 | 2002-02-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200404718B true ZA200404718B (en) | 2006-11-29 |
Family
ID=27663244
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200404718A ZA200404718B (en) | 2002-02-01 | 2004-06-14 | Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor |
Country Status (24)
Country | Link |
---|---|
US (1) | US20030198674A1 (de) |
EP (1) | EP1474144B1 (de) |
JP (1) | JP2005522424A (de) |
KR (1) | KR20040083493A (de) |
CN (1) | CN1625397A (de) |
AR (1) | AR038385A1 (de) |
AT (1) | ATE403432T1 (de) |
BR (1) | BR0307332A (de) |
CA (1) | CA2473991C (de) |
DE (1) | DE60322665D1 (de) |
ES (1) | ES2309294T3 (de) |
GT (1) | GT200300023A (de) |
HN (1) | HN2003000054A (de) |
IL (1) | IL162870A0 (de) |
MX (1) | MXPA04005647A (de) |
NO (1) | NO20043506L (de) |
PA (1) | PA8565101A1 (de) |
PE (1) | PE20030806A1 (de) |
PL (1) | PL371416A1 (de) |
RU (1) | RU2004123637A (de) |
TW (1) | TW200303204A (de) |
UY (1) | UY27643A1 (de) |
WO (1) | WO2003063868A1 (de) |
ZA (1) | ZA200404718B (de) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0307333A (pt) | 2002-02-01 | 2004-12-07 | Pfizer Prod Inc | Métodos para a preparação de dispersões homogéneas de fármacos sólidos amorfos atomizados utilizando um sistema de secagem por pulverização |
GB0203296D0 (en) | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel composition |
US8637512B2 (en) | 2002-07-29 | 2014-01-28 | Glaxo Group Limited | Formulations and method of treatment |
US20040122048A1 (en) * | 2002-10-11 | 2004-06-24 | Wyeth Holdings Corporation | Stabilized pharmaceutical composition containing basic excipients |
AU2003283769A1 (en) * | 2002-12-20 | 2004-07-14 | Pfizer Products Inc. | Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor |
WO2004085996A2 (en) * | 2003-03-20 | 2004-10-07 | Albert Einstein College Of Medicine Of Yeshiva University | Biomarkers for longevity and disease and uses thereof |
CL2004001884A1 (es) * | 2003-08-04 | 2005-06-03 | Pfizer Prod Inc | Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros. |
PL1670768T3 (pl) | 2003-10-08 | 2010-01-29 | Lilly Co Eli | Związki i sposoby leczenia dyslipidemii |
ATE500819T1 (de) * | 2003-12-31 | 2011-03-15 | Bend Res Inc | Stabilisierte pharmazeutische feste zusammensetzungen von arzneimitteln mit geringer löslichkeit, poloxameren und stabilisierenden polymeren |
ES2308477T3 (es) | 2004-03-26 | 2008-12-01 | Eli Lilly And Company | Compuestos para el tratamiento de la dislipidemia. |
UA90269C2 (ru) | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
TWI345568B (en) | 2004-04-02 | 2011-07-21 | Mitsubishi Tanabe Pharma Corp | Tetrahydronaphthyridine derivatives and a process for preparing the same |
US7700774B2 (en) * | 2004-12-20 | 2010-04-20 | Dr. Reddy's Laboratories Ltd. | Heterocyclic compounds and their pharmaceutical compositions |
US8604055B2 (en) * | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
CA2605214C (en) | 2004-12-31 | 2016-07-12 | Reddy Us Therapeutics, Inc. | Benzylamine derivatives as cetp inhibitors |
US9265731B2 (en) * | 2005-01-28 | 2016-02-23 | Bend Research, Inc. | Drying of drug-containing particles |
US20080145427A1 (en) * | 2005-02-03 | 2008-06-19 | Alfred Berchielli | Dosage Forms Providing Controlled and Immediate Release of Cholesteryl Ester Transfer Protein Inhibitors and Immediate Release of Hmg-Coa Reductase Inhibitors |
WO2006098394A1 (ja) * | 2005-03-14 | 2006-09-21 | Japan Tobacco Inc. | 脂質吸収抑制方法および脂質吸収抑制剤 |
UY30117A1 (es) | 2006-01-31 | 2007-06-29 | Tanabe Seiyaku Co | Compuesto amina trisustituido |
PE20071025A1 (es) | 2006-01-31 | 2007-10-17 | Mitsubishi Tanabe Pharma Corp | Compuesto amina trisustituido |
KR101418267B1 (ko) * | 2006-02-09 | 2014-07-11 | 머크 샤프 앤드 돔 코포레이션 | Cetp 억제제의 중합체 제형 |
GB0613925D0 (en) * | 2006-07-13 | 2006-08-23 | Unilever Plc | Improvements relating to nanodispersions |
WO2008012617A1 (en) * | 2006-07-21 | 2008-01-31 | Pfizer Products Inc. | Drying of drug-containing particles |
US7750019B2 (en) | 2006-08-11 | 2010-07-06 | Kowa Company, Ltd. | Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same |
WO2008065506A2 (en) * | 2006-11-29 | 2008-06-05 | Pfizer Products Inc. | Pharmaceutical compositions comprising nanoparticles comprising enteric polymers and casein |
WO2008065502A1 (en) * | 2006-11-29 | 2008-06-05 | Pfizer Products Inc. | Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein |
US7790737B2 (en) | 2007-03-13 | 2010-09-07 | Kowa Company, Ltd. | Substituted pyrimidine compounds and their utility as CETP inhibitors |
US8105625B2 (en) * | 2007-04-05 | 2012-01-31 | University Of Kansas | Rapidly dissolving pharmaceutical compositions comprising pullulan |
US8900629B2 (en) | 2007-04-05 | 2014-12-02 | University Of Kansas | Rapidly dissolving pharmaceutical compositions comprising pullulan |
NZ580777A (en) | 2007-04-13 | 2011-05-27 | Kowa Co | Novel pyrimidine compound having dibenzylamine structure, and medicine comprising the compound |
WO2008135855A2 (en) * | 2007-05-03 | 2008-11-13 | Pfizer Products Inc. | Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer |
ES2692437T3 (es) * | 2007-08-13 | 2018-12-03 | Abuse Deterrent Pharmaceutical Llc | Fármacos resistentes al abuso, método de uso y método de preparación |
MX2011013080A (es) * | 2009-06-16 | 2012-01-20 | Pfizer | Formas de dosis de apixaban. |
EP2744803A2 (de) | 2011-08-18 | 2014-06-25 | Dr. Reddy's Laboratories Ltd. | Substituierte heterocyclische aminverbindungen als cholestryl-ester-transfer-protein (cetp)-inhibitoren |
JP6140168B2 (ja) | 2011-09-27 | 2017-05-31 | ドクター レディズ ラボラトリーズ リミテッド | アテローム性動脈硬化症の処置のために有用なコレステリルエステル転送タンパク質(cetp)インヒビターとしての5−ベンジルアミノメチル−6−アミノピラゾロ[3,4−b]ピリジン誘導体 |
US20140275149A1 (en) | 2013-03-15 | 2014-09-18 | Inspirion Delivery Technologies, Llc | Abuse deterrent compositions and methods of use |
KR101610465B1 (ko) | 2014-04-11 | 2016-04-07 | 국립암센터 | 다목적용 의료 영상 표지자 및 이의 제조방법 |
US10729685B2 (en) | 2014-09-15 | 2020-08-04 | Ohemo Life Sciences Inc. | Orally administrable compositions and methods of deterring abuse by intranasal administration |
CN104474553A (zh) * | 2014-11-26 | 2015-04-01 | 嘉应学院医学院 | 一种基于β-谷甾醇的药物缓释剂及其制备方法 |
CN107098946B (zh) * | 2016-02-23 | 2021-01-29 | 中国药科大学 | Cetp抑制剂的合成与用途 |
EP3990845B1 (de) | 2019-06-26 | 2024-04-17 | Carrier Corporation | Transportkühleinheit mit adaptiver abtauung |
CN116472044A (zh) * | 2020-09-18 | 2023-07-21 | 百时美施贵宝公司 | 包含可溶胀核芯的Tyk2抑制剂的剂型 |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US28895A (en) * | 1860-06-26 | Machine for wetting paper | ||
US91643A (en) * | 1869-06-22 | Improvement in gang-plows | ||
US18446A (en) * | 1857-10-20 | Improvement in steam-plows | ||
US54038A (en) * | 1866-04-17 | Improvement in priming metallic cartridges | ||
US3995631A (en) | 1971-01-13 | 1976-12-07 | Alza Corporation | Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US4247498A (en) | 1976-08-30 | 1981-01-27 | Akzona Incorporated | Methods for making microporous products |
US4564488A (en) | 1978-07-31 | 1986-01-14 | Akzo Nv | Methods for the preparation of porous fibers and membranes |
CA1146866A (en) | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
US4490431A (en) | 1982-11-03 | 1984-12-25 | Akzona Incorporated | 0.1 Micron rated polypropylene membrane and method for its preparation |
US4612008A (en) | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
US5225192A (en) | 1988-10-17 | 1993-07-06 | Vectorpharma International S.P.A. | Poorly soluble medicaments supported on polymer substances in a form suitable for increasing their dissolving rate |
DE3438830A1 (de) | 1984-10-23 | 1986-04-30 | Rentschler Arzneimittel | Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung |
DE3612212A1 (de) | 1986-04-11 | 1987-10-15 | Basf Ag | Verfahren zur herstellung von festen pharmazeutischen formen |
US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Hydrogel-operated release devices |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
ES2111065T5 (es) | 1991-04-16 | 2005-06-16 | Nippon Shinyaku Company, Limited | Procedimiento para producir una dispersion solida. |
US5340591A (en) | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
JP3265680B2 (ja) | 1992-03-12 | 2002-03-11 | 大正製薬株式会社 | 経口製剤用組成物 |
DE4316537A1 (de) | 1993-05-18 | 1994-11-24 | Basf Ag | Zubereitungen in Form fester Lösungen |
DE4327063A1 (de) | 1993-08-12 | 1995-02-16 | Kirsten Dr Westesen | Ubidecarenon-Partikel mit modifizierten physikochemischen Eigenschaften |
US6054136A (en) | 1993-09-30 | 2000-04-25 | Gattefosse S.A. | Orally administrable composition capable of providing enhanced bioavailability when ingested |
US5458887A (en) | 1994-03-02 | 1995-10-17 | Andrx Pharmaceuticals, Inc. | Controlled release tablet formulation |
DE4440337A1 (de) | 1994-11-11 | 1996-05-15 | Dds Drug Delivery Services Ges | Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit |
JPH09501186A (ja) * | 1994-11-12 | 1997-02-04 | 株式会社エルジ化学 | コレステリルエステル運搬蛋白質阻害ペプチドおよびこれを含む動脈硬化症のための予防および治療剤 |
DE19504832A1 (de) | 1995-02-14 | 1996-08-22 | Basf Ag | Feste Wirkstoff-Zubereitungen |
SI9500173B (sl) | 1995-05-19 | 2002-02-28 | Lek, | Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo |
US5654005A (en) | 1995-06-07 | 1997-08-05 | Andrx Pharmaceuticals, Inc. | Controlled release formulation having a preformed passageway |
US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
US5686133A (en) | 1996-01-31 | 1997-11-11 | Port Systems, L.L.C. | Water soluble pharmaceutical coating and method for producing coated pharmaceuticals |
US5993858A (en) | 1996-06-14 | 1999-11-30 | Port Systems L.L.C. | Method and formulation for increasing the bioavailability of poorly water-soluble drugs |
DE19627431A1 (de) * | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
HRP970330B1 (en) * | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
US6046177A (en) | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
US5874418A (en) | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
GT199900147A (es) * | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
US6147090A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
US6140342A (en) * | 1998-09-17 | 2000-10-31 | Pfizer Inc. | Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines |
US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
DE69935992T4 (de) | 1998-09-25 | 2008-05-29 | Monsanto Co., Chicago | Polycyclische aryl und heteroaryl substituierte tertiäre heteroalkylamine, für die hemmung der aktivität des cholesteryl-ester-transfer-proteins |
US6174873B1 (en) * | 1998-11-04 | 2001-01-16 | Supergen, Inc. | Oral administration of adenosine analogs |
ATE404178T1 (de) * | 1999-02-10 | 2008-08-15 | Pfizer Prod Inc | Vorrichtung mit matrixgesteuerter wirkstofffreisetzung |
US6706283B1 (en) | 1999-02-10 | 2004-03-16 | Pfizer Inc | Controlled release by extrusion of solid amorphous dispersions of drugs |
EP1712222A3 (de) | 1999-12-23 | 2012-06-20 | Pfizer Products Inc. | Arzneizusammensetzung mit erhöhter Arzneistoffkonzentration |
DE60038698T2 (de) * | 1999-12-23 | 2009-05-07 | Pfizer Products Inc., Groton | Hydrogel-gesteuerte dosierungsform |
US7115279B2 (en) | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
JP4547148B2 (ja) * | 2001-06-22 | 2010-09-22 | ベンド・リサーチ・インコーポレーテッド | 非晶質薬剤の吸着物の医薬組成物 |
EP1269994A3 (de) | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmazeutische Zusammensetzungen die ein Arzneimittel und die Konzentration verbesserende Polymere enthalten |
JP4644397B2 (ja) * | 2001-09-05 | 2011-03-02 | 信越化学工業株式会社 | 難溶性薬物を含む医薬用固形製剤の製造方法 |
AR038375A1 (es) | 2002-02-01 | 2005-01-12 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo |
-
2003
- 2003-01-20 MX MXPA04005647A patent/MXPA04005647A/es unknown
- 2003-01-20 EP EP03700414A patent/EP1474144B1/de not_active Expired - Lifetime
- 2003-01-20 PL PL03371416A patent/PL371416A1/xx not_active Application Discontinuation
- 2003-01-20 RU RU2004123637/15A patent/RU2004123637A/ru not_active Application Discontinuation
- 2003-01-20 AT AT03700414T patent/ATE403432T1/de not_active IP Right Cessation
- 2003-01-20 CN CNA038030438A patent/CN1625397A/zh active Pending
- 2003-01-20 JP JP2003563558A patent/JP2005522424A/ja active Pending
- 2003-01-20 KR KR10-2004-7011853A patent/KR20040083493A/ko not_active Application Discontinuation
- 2003-01-20 BR BR0307332-7A patent/BR0307332A/pt not_active IP Right Cessation
- 2003-01-20 ES ES03700414T patent/ES2309294T3/es not_active Expired - Lifetime
- 2003-01-20 WO PCT/IB2003/000209 patent/WO2003063868A1/en active IP Right Grant
- 2003-01-20 CA CA002473991A patent/CA2473991C/en not_active Expired - Fee Related
- 2003-01-20 DE DE60322665T patent/DE60322665D1/de not_active Expired - Fee Related
- 2003-01-20 IL IL16287003A patent/IL162870A0/xx unknown
- 2003-01-23 US US10/349,600 patent/US20030198674A1/en not_active Abandoned
- 2003-01-29 PE PE2003000098A patent/PE20030806A1/es not_active Application Discontinuation
- 2003-01-30 HN HN2003000054A patent/HN2003000054A/es unknown
- 2003-01-30 GT GT200300023A patent/GT200300023A/es unknown
- 2003-01-30 TW TW092102281A patent/TW200303204A/zh unknown
- 2003-01-31 AR ARP030100294A patent/AR038385A1/es unknown
- 2003-01-31 UY UY27643A patent/UY27643A1/es not_active Application Discontinuation
- 2003-02-03 PA PA20038565101A patent/PA8565101A1/es unknown
-
2004
- 2004-06-14 ZA ZA200404718A patent/ZA200404718B/en unknown
- 2004-08-23 NO NO20043506A patent/NO20043506L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
UY27643A1 (es) | 2003-08-29 |
EP1474144B1 (de) | 2008-08-06 |
JP2005522424A (ja) | 2005-07-28 |
NO20043506L (no) | 2004-10-19 |
ES2309294T3 (es) | 2008-12-16 |
BR0307332A (pt) | 2004-12-07 |
HN2003000054A (es) | 2003-11-24 |
MXPA04005647A (es) | 2005-03-23 |
KR20040083493A (ko) | 2004-10-02 |
RU2004123637A (ru) | 2005-04-20 |
ATE403432T1 (de) | 2008-08-15 |
IL162870A0 (en) | 2005-11-20 |
US20030198674A1 (en) | 2003-10-23 |
CA2473991C (en) | 2009-09-15 |
WO2003063868A1 (en) | 2003-08-07 |
GT200300023A (es) | 2003-09-17 |
PL371416A1 (en) | 2005-06-13 |
EP1474144A1 (de) | 2004-11-10 |
CN1625397A (zh) | 2005-06-08 |
PA8565101A1 (es) | 2003-11-12 |
CA2473991A1 (en) | 2003-08-07 |
AR038385A1 (es) | 2005-01-12 |
PE20030806A1 (es) | 2003-09-19 |
DE60322665D1 (de) | 2008-09-18 |
TW200303204A (en) | 2003-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200404718B (en) | Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor | |
JP6581625B2 (ja) | 代謝障害を治療するための組成物および方法 | |
JP6837486B2 (ja) | 加齢に関連する認知障害及び神経炎症を予防及び/又は治療する方法 | |
EP3110427A1 (de) | Zusammensetzungen von pentosanpolysulfatsalzen zur oralen verabreichung und verfahren zur verwendung | |
AU2018357350B2 (en) | Delayed release deferiprone tablets and methods of using the same | |
US20080286354A1 (en) | Composition and therapies for hyperlipidaemia-associated disorders | |
JP2016504384A (ja) | ビグアナイドを含む遅延放出組成物 | |
US20090075950A1 (en) | Dosage Forms Containing A PPI, NSAID And A Buffer | |
US7834056B2 (en) | Pharmaceutical composition for gout | |
JP2004091473A (ja) | 色素沈着改善治療薬 | |
BR112020017056A2 (pt) | Composição farmacêutica compreendendo remogliflozina e um agente antidiabético | |
EA029157B1 (ru) | Терапия макулярной дегенерации на основе баклофена и акампросата | |
EP1465607B1 (de) | Pharmazeutische zusammensetzung mit modifizierter freisetzung | |
US20210290580A1 (en) | New use of carbamate ß phenylethanolamine analogues for enhancing intracellular clearance of LDL cholesterol and for combining therapy with statins to enhance the efficacy and reduce adverse effects | |
US20220192999A1 (en) | Use of gold nanoclusters in treating hypercholesterolemia or hypercholesterolemia-associated diseases | |
US20100305074A1 (en) | Niacin-based pharmaceutical compositions | |
WO2024108501A1 (zh) | 丙泊酚的抗焦虑制药用途及抗焦虑药物制剂 | |
AU2001250174B2 (en) | Compositions and therapies for hyperlipidaemia-associated disorders | |
US20110076334A1 (en) | Methods and compositions for treatment of raynaud's phenomenon | |
BR112015016111B1 (pt) | Composição farmacêutica de liberação retardada para entrega de composto de biguanida e uso de um composto de biguanida ou sal do mesmo |